These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 38405079)
41. Low-Dose Aspirin Upregulates Tyrosine Hydroxylase and Increases Dopamine Production in Dopaminergic Neurons: Implications for Parkinson's Disease. Rangasamy SB; Dasarathi S; Pahan P; Jana M; Pahan K J Neuroimmune Pharmacol; 2019 Jun; 14(2):173-187. PubMed ID: 30187283 [TBL] [Abstract][Full Text] [Related]
42. Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. Kastner A; Hirsch EC; Herrero MT; Javoy-Agid F; Agid Y J Neurochem; 1993 Sep; 61(3):1024-34. PubMed ID: 8103078 [TBL] [Abstract][Full Text] [Related]
43. Identification of potential therapeutic compounds for Parkinson's disease using Drosophila and human cell models. Sanz FJ; Solana-Manrique C; Muñoz-Soriano V; Calap-Quintana P; Moltó MD; Paricio N Free Radic Biol Med; 2017 Jul; 108():683-691. PubMed ID: 28455141 [TBL] [Abstract][Full Text] [Related]
44. Assessing neurodegenerative phenotypes in Drosophila dopaminergic neurons by climbing assays and whole brain immunostaining. Barone MC; Bohmann D J Vis Exp; 2013 Apr; (74):e50339. PubMed ID: 23644755 [TBL] [Abstract][Full Text] [Related]
45. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease. Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185 [TBL] [Abstract][Full Text] [Related]
46. Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection. Stephenson D; Ramirez A; Long J; Barrezueta N; Hajos-Korcsok E; Matherne C; Gallagher D; Ryan A; Ochoa R; Menniti F; Yan J J Neurosci Methods; 2007 Jan; 159(2):291-9. PubMed ID: 16949674 [TBL] [Abstract][Full Text] [Related]
47. Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease. Heo JY; Nam MH; Yoon HH; Kim J; Hwang YJ; Won W; Woo DH; Lee JA; Park HJ; Jo S; Lee MJ; Kim S; Shim JE; Jang DP; Kim KI; Huh SH; Jeong JY; Kowall NW; Lee J; Im H; Park JH; Jang BK; Park KD; Lee HJ; Shin H; Cho IJ; Hwang EM; Kim Y; Kim HY; Oh SJ; Lee SE; Paek SH; Yoon JH; Jin BK; Kweon GR; Shim I; Hwang O; Ryu H; Jeon SR; Lee CJ Curr Biol; 2020 Jan; 30(2):276-291.e9. PubMed ID: 31928877 [TBL] [Abstract][Full Text] [Related]
48. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease. Zuo L; Motherwell MS Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870 [TBL] [Abstract][Full Text] [Related]
49. In vivo detection of lateral-ventral tier nigral degeneration in Parkinson's disease. Huddleston DE; Langley J; Sedlacik J; Boelmans K; Factor SA; Hu XP Hum Brain Mapp; 2017 May; 38(5):2627-2634. PubMed ID: 28240402 [TBL] [Abstract][Full Text] [Related]
50. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. Ichinose H; Ohye T; Fujita K; Pantucek F; Lange K; Riederer P; Nagatsu T J Neural Transm Park Dis Dement Sect; 1994; 8(1-2):149-58. PubMed ID: 7893377 [TBL] [Abstract][Full Text] [Related]
51. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. Nordströma U; Beauvais G; Ghosh A; Pulikkaparambil Sasidharan BC; Lundblad M; Fuchs J; Joshi RL; Lipton JW; Roholt A; Medicetty S; Feinstein TN; Steiner JA; Escobar Galvis ML; Prochiantz A; Brundin P Neurobiol Dis; 2015 Jan; 73():70-82. PubMed ID: 25281317 [TBL] [Abstract][Full Text] [Related]
52. Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration. Kim J; Jang S; Choi M; Chung S; Choe Y; Choe HK; Son GH; Rhee K; Kim K Mol Cells; 2018 Aug; 41(8):742-752. PubMed ID: 30078232 [TBL] [Abstract][Full Text] [Related]
53. Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers. Killinger BA; Moszczynska A J Neurochem; 2016 Feb; 136(3):510-25. PubMed ID: 26465779 [TBL] [Abstract][Full Text] [Related]
54. A simple and fast densitometric method for the analysis of tyrosine hydroxylase immunoreactivity in the substantia nigra pars compacta and in the ventral tegmental area. Xavier LL; Viola GG; Ferraz AC; Da Cunha C; Deonizio JM; Netto CA; Achaval M Brain Res Brain Res Protoc; 2005 Dec; 16(1-3):58-64. PubMed ID: 16310404 [TBL] [Abstract][Full Text] [Related]
55. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI. Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909 [TBL] [Abstract][Full Text] [Related]
56. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse. Savolainen MH; Albert K; Airavaara M; Myöhänen TT Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627 [TBL] [Abstract][Full Text] [Related]
57. Ginsenoside Rb1 protects dopaminergic neurons from inflammatory injury induced by intranigral lipopolysaccharide injection. Li DW; Zhou FZ; Sun XC; Li SC; Yang JB; Sun HH; Wang AH Neural Regen Res; 2019 Oct; 14(10):1814-1822. PubMed ID: 31169200 [TBL] [Abstract][Full Text] [Related]
58. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
59. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse. Perfeito R; Cunha-Oliveira T; Rego AC Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292 [TBL] [Abstract][Full Text] [Related]